search
Back to results

The Mount Sinai Diabetic Foot Ulcer Prospective Trial

Primary Purpose

Diabetes, Diabetic Foot Ulcer, Edema

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Conventional Therapy
Venous Stent(s)
Sponsored by
Windsor Ting
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes focused on measuring DFU, Vein, Stent

Eligibility Criteria

30 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Presence of diabetic foot ulcer within the foot (located distal to the ankle and proximal to base of toes)
  • Lower extremity edema
  • MRA or CTA showing stenosis of iliac vein or indirect findings that suggest presence of iliac vein stenosis (distal venous dilation and presence of collateral veins)
  • At least one palpable pedal pulse or ABI>0.9 IVUS confirmation of iliac vein stenosis

Exclusion Criteria:

  • Previous vein stent implantation involving study leg or inferior vena cava
  • Previous bypass surgery or endovascular intervention involving study leg
  • Known metal allergy
  • Known reaction or sensitivity to iodinated contrast that cannot be managed with premedication
  • Acute deep venous thrombosis involving either leg
  • Known history of chronic occlusion of any vein in the study leg
  • Venous compression caused by tumor encasement
  • Venous outflow obstruction caused by tumor thrombus
  • Elevated baseline blood creatinine (>1.5)
  • Pregnancy
  • Life expectancy <12 months

Sites / Locations

  • Icahn School of Medicine at Mount SinaiRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Sham Comparator

Active Comparator

Arm Label

Conventional Therapy

Conventional Therapy + venous stent(s)

Arm Description

Conventional therapy of DFU comprises of four components: local wound care, antibiotic therapy, debridement and amputation, and pressure offloading.

Patients will receive a venous stent in addition to conventional therapy

Outcomes

Primary Outcome Measures

Number of days to ulcer healing
All patient subjects with an active ulcer will be followed until healing of the ulcer.

Secondary Outcome Measures

Number of subjects whose DFU persisted
Number of subjects whose DFU persisted 12 months post-randomization
Number of recurrent DFU
Number of subjects who had recurrent DFU 12 months post-randomization
Total number of subjects with limb loss
Number of subjects who had limb loss within 12 months post-randomization
Total number of subjects with minor and major amputations
Number of subjects who had major or minor amputations within 12 months post-randomization

Full Information

First Posted
January 12, 2018
Last Updated
October 3, 2022
Sponsor
Windsor Ting
search

1. Study Identification

Unique Protocol Identification Number
NCT03404895
Brief Title
The Mount Sinai Diabetic Foot Ulcer Prospective Trial
Official Title
The Mount Sinai Diabetic Foot Ulcer Prospective Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 13, 2018 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Windsor Ting

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate whether placing stent(s) for a blockage in a leg vein will help improve the healing of diabetic foot ulcers (DFU). The investigators know from having taken care of many patients with diabetic foot ulcers that it is a major cause of disability and amputation. These diabetic foot ulcers frequently heal slowly or not at all. They sometimes become infected and require antibiotic therapy, debridement and amputation. The investigators normally take care of a diabetic foot ulcer with a combination of local wound care, surgical debridement if necessary, antibiotics if there is an infection, and reduction of pressure on the area of the foot with the ulcer. The investigators observed that some patients with a diabetic foot ulcer also have a blockage in a major leg vein referred to as the iliac vein. This blockage in the iliac vein prevents the proper flow of blood from the leg. This blockage results in pressure within the leg veins leading to swelling in the legs which may also prevent healing of the diabetic foot ulcer. This study will investigate whether placing stent(s) to treat the blockage(s) will improve healing of the diabetic foot ulcer and reduce some of the complications associated with a diabetic foot ulcer. The results of this study could result in a new treatment that will allow future patients with diabetic foot ulcers to heal better. Right now, placing stents for these blockages in the iliac vein is not the standard of care treatment for a diabetic foot ulcer. In order for us to determine whether stent placement is helpful, the researchers will have to randomize each patient. In other words, to reduce bias, patients will be assigned either to a group receiving a stent or to a group not receiving a stent. Every patient in both groups will receive the standard of care for a diabetic foot ulcer and undergo an x-ray with contrast and intravenous ultrasound examination of the legs. The standard of care for a diabetic foot ulcer may include local wound care, antibiotic therapy, debridement and/or amputation, and pressure offloading in the foot.
Detailed Description
This will be a single center, patient-blinded, randomized controlled trial. In the event that a patient does not meet inclusion criteria after signing the consent for and undergoing venogram/IVUS (screen fail), additional patients will be enrolled until 60 patients have been successfully randomized. Up to 80 patients will be consented in order to account for potential screen fails. Randomized patients will be followed monthly until their ulcer heals, every 3 months after healing for one year postoperatively. Every patient subject will undergo venogram & IVUS. The investigator experience with over 600 patients who underwent venous stenting at Mount Sinai - all of whom had preoperative MR venogram or CT venogram - revealed that pre-operative imaging missed the diagnosis of PVOO in approximately 10% of patients (this is unpublished data). Due to the small sample size of this pilot study, the very low risks associated with venogram and IVUS, and the 100% accuracy of venogram and IVUS in diagnosing PVOO, every study subject will undergo these two imaging studies. Once the diagnosis of PVOO is confirmed, the study subject will be immediately randomized in the OR. Study subjects randomized to convention therapy plus venous stents will undergo venous stent placement at the same sitting. For study subjects randomized to conventional therapy alone, the procedure will be terminated after venogram and IVUS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetic Foot Ulcer, Edema
Keywords
DFU, Vein, Stent

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Subjects are randomized in the OR to one of two study arms: conventional therapy vs. conventional therapy + venous stent(s).
Masking
Participant
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Conventional Therapy
Arm Type
Sham Comparator
Arm Description
Conventional therapy of DFU comprises of four components: local wound care, antibiotic therapy, debridement and amputation, and pressure offloading.
Arm Title
Conventional Therapy + venous stent(s)
Arm Type
Active Comparator
Arm Description
Patients will receive a venous stent in addition to conventional therapy
Intervention Type
Device
Intervention Name(s)
Conventional Therapy
Intervention Description
Local wound care consists of at least once daily dressing Occasionally, a limited bedside debridement is indicated to excise small quantity of devitalized tissues and to provide better drainage. Antibiotic therapy including both gram-positive and gram-negative coverage when the DFU appears infected is guided by wound cultures and when necessary, Infectious Disease consultation. Debridement and amputation will be performed as clinically indicated. To promote healing after the more acute processes have been addressed, pressure offloading is frequently helpful in the healing of DFU. Pressure offloading treatment ranges from special dressings and devices to special diabetic foot wares. Offloading will be utilized as indicated.
Intervention Type
Device
Intervention Name(s)
Venous Stent(s)
Intervention Description
After PVOO is confirmed by venography and IVUS, and patient subject is randomized to conventional therapy and stent placement, stent placement is performed immediately at the same sitting.
Primary Outcome Measure Information:
Title
Number of days to ulcer healing
Description
All patient subjects with an active ulcer will be followed until healing of the ulcer.
Time Frame
average of 1 year
Secondary Outcome Measure Information:
Title
Number of subjects whose DFU persisted
Description
Number of subjects whose DFU persisted 12 months post-randomization
Time Frame
12 months
Title
Number of recurrent DFU
Description
Number of subjects who had recurrent DFU 12 months post-randomization
Time Frame
12 months
Title
Total number of subjects with limb loss
Description
Number of subjects who had limb loss within 12 months post-randomization
Time Frame
12 months
Title
Total number of subjects with minor and major amputations
Description
Number of subjects who had major or minor amputations within 12 months post-randomization
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Presence of diabetic foot ulcer within the foot (located distal to the ankle and proximal to base of toes) Lower extremity edema MRA or CTA showing stenosis of iliac vein or indirect findings that suggest presence of iliac vein stenosis (distal venous dilation and presence of collateral veins) At least one palpable pedal pulse or ABI>0.9 IVUS confirmation of iliac vein stenosis Exclusion Criteria: Previous vein stent implantation involving study leg or inferior vena cava Previous bypass surgery or endovascular intervention involving study leg Known metal allergy Known reaction or sensitivity to iodinated contrast that cannot be managed with premedication Acute deep venous thrombosis involving either leg Known history of chronic occlusion of any vein in the study leg Venous compression caused by tumor encasement Venous outflow obstruction caused by tumor thrombus Elevated baseline blood creatinine (>1.5) Pregnancy Life expectancy <12 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Abbey Foote, BS
Phone
212-241-8250
Email
abbey.foote@mountsinai.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Windsor Ting, MD
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
Facility Information:
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Windsor Ting, MD

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

The Mount Sinai Diabetic Foot Ulcer Prospective Trial

We'll reach out to this number within 24 hrs